PMID- 32520652
OWN - NLM
STAT- Publisher
LR  - 20240227
IS  - 0743-6661 (Print)
IS  - 0743-6661 (Linking)
DP  - 2020 Jun 10
TI  - Type 2 Diabetes in China - Considering Both Insurance Products and Individual 
      Health Factors.
LID - 10.17849/insm-48-2-1-5.1 [doi]
AB  - For the past 30 years, the increase in the prevalence of type 2 diabetes mellitus 
      (T2DM) in China has reached epidemic proportions. As a result, risk assessment 
      guidelines need to be updated by taking into consideration of improvements in 
      medical treatment and lifestyle intervention. This especially applies to living 
      insurance benefit policies (such as critical illness and total permanent 
      disability) and to medical products (hospitalization reimbursement and certain 
      DM-related treatment benefits). This will require taking into account the current 
      epidemic figures of T2DM in China in pricing, targeting the correct insured group 
      for the DM products and getting the correct risk profile by applying a dynamic 
      underwriting protocol (such as using the rewards for medical intervention, and 
      for primary prevention efforts to screen individuals who are at high-risk of 
      diabetes). This article analyzes both studies and surveys that been conducted in 
      China showing the progress of this epidemic.
FAU - Ying, Celia Zhang
AU  - Ying CZ
LA  - eng
PT  - Journal Article
DEP - 20200610
PL  - United States
TA  - J Insur Med
JT  - Journal of insurance medicine (New York, N.Y.)
JID - 8401468
OTO - NOTNLM
OT  - China
OT  - Insurance
OT  - Prevalence
OT  - Risk Assessment
OT  - T2DM
OT  - Type 2 diabetes mellitus
EDAT- 2020/06/11 06:00
MHDA- 2020/06/11 06:00
CRDT- 2020/06/11 06:00
PHST- 2020/06/11 06:00 [entrez]
PHST- 2020/06/11 06:00 [pubmed]
PHST- 2020/06/11 06:00 [medline]
AID - 10.17849/insm-48-2-1-5.1 [doi]
PST - aheadofprint
SO  - J Insur Med. 2020 Jun 10. doi: 10.17849/insm-48-2-1-5.1.